CytoMed Therapeutics Ltd (GDTC) stock
GDTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.83+0.05 (+6.00%)
Close on Nov 18, 2026Market cap $9.82MP/E –Yield –
CytoMed Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
No operating income figures for CytoMed Therapeutics
CytoMed Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?